Palvella Therapeutics(PVLA)

Focus: Palvella Therapeutics is a public-stage biotechnology company focused on small-molecule therapeutics for rare and orphan dermatological and genetic conditions. The company operates with a lean structure and concentrated pipeline centered on topical and systemic treatments for underserved patient populations.

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Palvella Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Palvella Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

QTORIN 3.9% rapamycin anhydrous gel

Cutaneous Venous Malformations

PHASE_2

Clinical Trials (1)

NCT06653842A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

Phase 2

Help build intelligence for Palvella Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Phase 3 pipeline momentum: 5 programs in Phase 3 testing across indications including microcystic lymphatic malformations and pachyonychia congenita, with near-term regulatory catalysts
Rare disease focus: Targeting orphan indications with significant unmet medical needs and favorable regulatory pathways (accelerated approval potential)
Public company status with stabilizing cash position ($84M in FY 2025 vs. $7M in FY 2024), providing runway for late-stage development and clinical operations

Watch Out For

Pre-revenue model with $17.4M net loss in FY 2025 despite $84M cash; burn rate trajectory unclear and company has not yet achieved commercial traction
No active hiring posted (0 open roles); small or contracting headcount limits growth opportunities and suggests limited near-term expansion
Limited pipeline diversity: only 2 distinct molecular entities (QTORIN rapamycin gel and PTX-022) across 8 development programs, concentrating success on few candidates

Generated by Claude from Palvella Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PTX-022

BCCs in Gorlin Syndrome Patients

PHASE_2

Clinical Trials (1)

NCT04893486CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Phase 2

PTX-022

Microcystic Lymphatic Malformation

PHASE_2

Clinical Trials (1)

NCT05050149Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

Phase 2

PTX-022

Pachyonychia Congenita

PHASE_2_3

Clinical Trials (1)

NCT03920228Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Phase 2/3

QTORIN 3.9% Rapamycin Anhydrous Gel

Microcystic Lymphatic Malformation

PHASE_3

Clinical Trials (1)

NCT06239480SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Phase 3

PTX-022

Pachyonychia Congenita

PHASE_3

Clinical Trials (1)

NCT04520750VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

Phase 3

QTORIN 3.9% rapamycin anhydrous gel

Pachyonychia Congenita

PHASE_3

Clinical Trials (1)

NCT05180708A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

Phase 3

PTX-022

Pachyonychia Congenita

PHASE_3

Clinical Trials (2)

NCT05643872A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

Phase 3

NCT07552077A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 9 clinical trials

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

R&D Spend

$8M7%

Net Income

-$17M

Cash

$84M

Source: SEC 10-K Filing